Skip to main content

Table 10 Clinical data comparison of carriers versus non-carriers of MC1R variants

From: Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin

Feature

Carriers (+)

 

Non-carriers (-)

p (95% CI)

OR

R160W

multiplicity1

3/852 (3.5%)

 

6/3743 (1.6%)

n.s.

2.2

localization-skin4

2.45

 

1.3

n.s.

1.8

tumour type6

607/208/109/410

 

58/20/9/5

n.s.

 

R151C

multiplicity

3/73 (4.1%)

 

7/402 (1.7%)

n.s.

2.4

localization in skin

2.2

 

1.4

n.s.

1.5

tumour type

57/21/9/5

 

54/19/10/6

n.s.

 

V60L

multiplicity

2/78 (2.6%)

 

6/355 (1.7%)

n.s.

1.5

localization in skin

2.0

 

1.4

n.s.

1.4

tumour type

58/22/11/4

 

57/20/11/3

n.s.

 

R163Q

multiplicity

1/30 (3.3%)

 

8/355 (2.2%)

n.s.

1.5

localization in skin

1.9

 

1.5

n.s.

1.3

tumour type

60/19/10/5

 

58/18/9/5

n.s.

 
 

any of four variants positive

 

none of four variants positive

  

multiplicity

8/254 (3.1%)

 

1/149 (0.7%)

n.s.

4.8

localization in skin

2.2

 

1.0

0.0014 (1.35–3.63)

2.2

tumour type

61/21/8/5

 

60/20/9/4

n.s.

 
  1. 1synchronic or metachronic tumours
  2. 2number of multiple melanoma cases/total number of MC1R variant carriers
  3. 3number of multiple melanoma cases/total number of patients without MC1R variants
  4. 4regions of exposed skin: head, nape, neck, forearms, palms, shanks, feet; regions of unexposed skin: trunk, thighs, arms, buttocks
  5. 5unexposed to exposed skin ratio – number of melanomas in unexposed skin divided by number of melanomas in exposed skin
  6. 6types of melanoma: a) SSM-superficial spreading melanoma; b) NM-nodular melanoma; c) LM-lentigo melanoma; d) ALM-acral lentigo melanoma
  7. 7 SSM percentage
  8. 8 NM percentage
  9. 9 LM percentage
  10. 10 ALM percentage
Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287